Lack of association between thiazolidinediones and macular edema in type 2 diabetes: The ACCORD eye substudy

Archives of Ophthalmology

Volumn 128, Issue 3, 2010, Pages 312-318

  Ambrosius, Walter T ^a   Danis, Ronald P ^b   Goff Jr , David C ^a   Greven, Craig M ^a   Gerstein, Hertzel C ^c   Cohen, Robert M ^d   Riddle, Matthew C ^e   Miller, Michael E ^a   Buse, John B ^f   Bonds, Denise E ^g   Peterson, Kevin A ⁱ   Rosenberg, Yves D ^g   Perdue, Letitia H ^a   Esser, Barbara A ^b   Seaquist, Lea A ⁱ   Felicetta, James V ^j   Chew, Emily Y ^h  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^h NATIONAL EYE INSTITUTE   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

^j CARL T HAYDEN VA MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; PIOGLITAZONE; ROSIGLITAZONE;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE DURATION; DISEASE SEVERITY; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOSCOPY; PRIORITY JOURNAL; SEX DIFFERENCE; VISUAL ACUITY;

CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; LIGANDS; MACULAR EDEMA; MALE; MIDDLE AGED; ODDS RATIO; THIAZOLIDINEDIONES; VISUAL ACUITY;

EID: 77949294909     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2009.310     Document Type: Article

References (43)

1. Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol. 2005;123(9):1273-1275.
2. Ryan EH Jr, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina. 2006;26(5):562-570.
3. Kendall C, Wooltorton E. Rosiglitazone (Avandia) and macular edema. CMAJ. 2006; 174(5):623.
4. GlaxoSmithKline. "Dear Doctor" letter. GlaxoSmithKline Web site. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/-2005/avandia- avandamet-hpc-cps-eng.php. Accessed September 17, 2009.
5. GlaxoSmithKline. "Dear Doctor" letter. Food and Drug Administration Web site. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm150496.htm. Accessed September 17, 2009.
6. Takeda Pharmaceuticals America. Actos Prescribing Information. Takeda Pharmaceuticals America Web site. http://www.actos.com/actospro/prescribinginfo. aspx. Accessed September 17, 2009.
7. Ciardella AP. Partial resolution of diabetic macular oedema after systemic treatment with furosemide. Br J Ophthalmol. 2004;88(9):1224- 1225.
8. Shen LQ, Child A, Weber GM, Folkman J, Aiello LP. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol. 2008;126(6):793-799.
9. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IV: diabetic macular edema. Ophthalmology. 1984;91(12):1464-1474.
10. Wong TY, Klein R, Islam A, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141(3):446-455.
11. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XV: the long-term incidence of macular edema. Ophthalmology. 1995;102(1):7-16.
12. Klein R, Moss SE, Klein BE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XI: the incidence of macular edema. Ophthalmology. 1989;96(10):1501-1510.
13. Chew EY, Klein ML, Ferris FL III, et al. Association of elevated serum lipids with retinal hard exudate in diabetic retinopathy: Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol. 1996;114(9):1079-1084.
14. Klein BEK, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XIII: relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology. 1991;98(8):1261-1265.
15. Roy MS, Klein R. Macular edema and retinal hard exudates in African Americans with type 1 diabetes: the New Jersey 725. Arch Ophthalmol. 2001;119(2):251-259.
16. Miljanovic B, Glynn RJ, Nathan DM, Manson JE, Schaumberg DA. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes. 2004;53(11):2883-2892.
17. Dormandy JA, Charbonnel B, Eckland DJA, et al; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289.
18. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180-1188.
19. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471.
20. Home PD, Pocock SJ, Beck-Nielsen H, et al; RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med. 2007;357(1):28-38.
21. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med. 2007; 356(24):2522-2524.
22. Drazen JM, Morrissey S, Curfman GD. Rosiglitazone-continued uncertainty about safety. N Engl J Med. 2007;357(1):63-64.
23. Nathan DM. Rosiglitazone and cardiotoxity-weighing the evidence. N Engl J Med. 2007;357(1):64-66.
24. Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med. 2007;357(1):67-69.
25. Rosiglitazone: seeking a balanced perspective. Lancet. 2007;369(9576):1834.
26. Food and Drug Administration Web site. Prescribing Information for Avandia, a GlaxoSmithKline brand-name for rosiglitazone. http://www.accessdata. fda.gov/drugsatfda-docs/label/2007/021071s023lbl.pdf. Accessed September 17, 2009.
27. Chew EY, Ambrosius WT, Howard LT, et al; ACCORD Study Group. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD) trial. Am J Cardiol. 2007;99(12A):103i-111i.
28. Goff DC Jr, Gerstein HC, Ginsberg HN, et al; ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Am J Cardiol. 2007;99(12A)(suppl):4i-20i.
29. Buse JB, Bigger JT, Byington RP, et al; ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.Am J Cardiol. 2007;99(12A)(suppl):21i-33i.
30. Ferris FL III, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94(1):91-96.
31. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification, ETDRS Report Number 10. Ophthalmology. 1991;98(5)(suppl):786-806.
32. Wilkinson CP, Ferris FL III, Klein RE, et al; Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677-1682.
33. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology. 1987;94(7):761-774.
34. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13-22.
35. Hardin JW, Hilbe JM. Generalized Estimating Equations. Boca Raton, FL: Chapman & Hall/CRC Press; 2003.
36. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley & Sons Inc; 2000.
37. Hastie TJ, Tibshirani RJ. Generalized Additive Models. London, England: Chapman & Hall Ltd; 1990.
38. Chambers JM, Hastie TJ. Statistical Models in S. Pacific Grove, CA: Wadsworth & Cole; 1992.
39. Lin DY, Wei LJ, Ying Z. Model-checking techniques based on cumulative residuals. Biometrics. 2002;58(1):1-12.
40. SAS Institute Inc. SAS/STAT 9.1 User's Guide. Cary, NC: SAS Institute Inc; 2004.
41. Davis MD, Fisher MR, Gangnon RE, et al; Early Treatment Diabetic Retinopathy Study Research Group. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci. 1998;39(2):233-252.
42. Davis MD, Bressler SB, Aiello LP, et al; Diabetic Retinopathy Clinical Research Network Study Group. Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci. 2008;49(5):1745-1752.
43. Harrell FE Jr. Regression Modeling Strategies. New York, NY: Springer-Verlag; 2001.